A Phase II Trial of a MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Treated With CD40 Ligand/Gamma Interferon With Subcutaneous IL-2 for Patients With Metastatic Melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2; Melanoma vaccine
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 22 May 2014 Biomarkers information updated
- 01 Apr 2006 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 15 Oct 2005 New trial record.